Wednesday, February 07, 2018 9:57:05 AM
Data readout does selection ARS 1H17
Contract with U.S. Government for ARS 2H17
Initiation of pivotal study ARS NHP 2H17
Data readout phase 1 open label HCT 2H17
Preclinical data Fukushima 1H17
Preclinical data NYBC 1H17
U.S/Europe phase 3 study initiation 1Q17
Japan pivitol study initiation 2H17
Closing on JV deal with Sosei 1Q17
Data from IC multinational phase 2 early 2018
Interim results from Europe phase 3 CLI 2H18-1H19
And at the bottom with milestones for 12 months a couple more.
Initially trial hip fracture
Licensing deal JV with China.
Misses on vast majority of them. Some by 7 months now. So why the delay on preclinical data from Fukushima and NYBC. Having trouble enrolling mice?
But I'm ok with management.
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM